Market Cap 442.28B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 22.95
Forward PE 17.73
Profit Margin 6.91%
Debt to Equity Ratio -12.03
Volume 2,098,564
Avg Vol 6,944,488
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 99%
Beta 0.30
Analysts Strong Sell
Price Target $275.77

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
biolover
biolover Aug. 19 at 6:02 PM
$LLY $NVO $VKTX BL is bypassing novo , $ABBV and going head to head against Lilly 😂. What the hell is he seeing on efficacy from phase 3 ? > 4500 pts been on drug > 1 year I know tolerability is pristine
0 · Reply
VoidCapital
VoidCapital Aug. 19 at 4:47 PM
$ABBV continues building a diversified pharmaceutical portfolio with major exposure to immunology, oncology, neuroscience, and other healthcare markets. AERT’s gross margin improved from 24.6% to 29.1%, showing meaningful expansion in operating efficiency.
0 · Reply
GoforProMIS
GoforProMIS Aug. 19 at 4:17 PM
$PMN CEO Neil Warma attended and presented at Jefferies Healthcare, Oppenheimer CNS and at the Bio International Conference with the opportunity of 1to1 meetings. As the Alzheimer Conference took place on on 12-15 July the 4-6 week NDA analyses by the specialist of pharmaceutical companies should be done. IMO we have 5-12 pharmaceutical companies interested in PMN: Biogen /Eisai due to high Aria of Leqembi. Roche as they lost bn with Gantenerumab and need a solution. $ABBV $BMY $NVS are keen to get into neurology as partnership. Pfizer and Takeda looking for Episelect Platform!
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 19 at 3:15 PM
$SLS Yes/ Just sub in GPs and for AML --- recall $MRK Dr. Julie Cohen in Co-Authoring and Publishing the GPS Key Phase 2 Results, Recommended running a Phase 3 for GPS and Keytruda in Plat Resistant Ovarian Cancer. GPs Key Phase 2 MOS was BETTER (18.4 months) than the FDA Approved $IMGN Elahere (16.4 months) in the same exact Patient setting. $ABBV Bought IMGN for $10B based on this Data. And GPS is better.
0 · Reply
MissionControl
MissionControl Aug. 19 at 2:10 PM
$ABBV Great morning surprise. 👀
0 · Reply
HawkEye828
HawkEye828 Aug. 19 at 1:39 PM
Go Merck...PROK will easily blow past 95% once Rilparencel is appoved for Chronic Kidney disease. $PROK Analysts Sentiment Buy Price Target 6.250 Upside +369.92% prokidney.com/clinical-stud.... Phase 2 with 70% response rate for kidney disease. Phase 3 on deck. Riprencel cell therapy designed to delay or completely prevent the need for dialysis which is one of the highest Medicare expenses ...at $30 Billion a year/ 90k to 100k per patient. $RHHBY, $NVO, $LLY, $ABBV
0 · Reply
AXLFI_HQ
AXLFI_HQ Aug. 19 at 12:24 PM
$ABBV Companies are using acquisitions, divestitures, separations, and business combinations to gain scale, improve focus, unlock value, and optimize capital allocation. Learn more: https://axlfi.com/themes/379
0 · Reply
TMC101
TMC101 Aug. 19 at 10:20 AM
$ABBV 🤔
0 · Reply
KarinSparrow145
KarinSparrow145 Aug. 19 at 9:08 AM
$GENI $ABBV $SBET $DAL Genius Sports benefits from sports-data and betting partnerships, AbbVie benefits from diversified pharmaceutical demand, SBET remains highly speculative, and Delta benefits from travel demand and premium-airline activity. I'm watching contract growth, drug sales, funding, passenger demand, and margins.
0 · Reply
CDSTrading
CDSTrading Aug. 19 at 8:57 AM
$GENI $ABBV $SBET $DAL Genius Sports benefits from sports-data and betting partnerships, AbbVie benefits from diversified pharmaceutical demand, SBET remains highly speculative, and Delta benefits from travel demand and premium-airline activity. I'm watching contract growth, drug sales, funding, passenger demand, and margins.
0 · Reply
Latest News on ABBV
AbbVie Earnings Call Transcript: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 19 days ago

AbbVie Earnings Call Transcript: Q2 2026


AbbVie Earnings release: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 19 days ago

AbbVie Earnings release: Q2 2026


AbbVie Quarterly report: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 19 days ago

AbbVie Quarterly report: Q2 2026


AbbVie Reports Second-Quarter 2026 Financial Results

Jul 31, 2026, 7:47 AM EDT - 19 days ago

AbbVie Reports Second-Quarter 2026 Financial Results

ABBV


JUVÉDERM® Day Returns to U.S. on August 19

Jul 30, 2026, 8:00 AM EDT - 20 days ago

JUVÉDERM® Day Returns to U.S. on August 19

ABBV


AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

ABBV


AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 2 months ago

AbbVie's $11 Billion Immunology Bet

ABBV APGE


AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

ABBV APGE


AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Transcript: M&A announcement


AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Slides: M&A announcement


AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Press release: M&A announcement


AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

ABBV APGE


AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 2 months ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

ABBV APGE


AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 2 months ago

AbbVie Declares Quarterly Dividend

ABBV


US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 2 months ago

US FDA approves AbbVie's rare blood cancer drug

ABBV


biolover
biolover Aug. 19 at 6:02 PM
$LLY $NVO $VKTX BL is bypassing novo , $ABBV and going head to head against Lilly 😂. What the hell is he seeing on efficacy from phase 3 ? > 4500 pts been on drug > 1 year I know tolerability is pristine
0 · Reply
VoidCapital
VoidCapital Aug. 19 at 4:47 PM
$ABBV continues building a diversified pharmaceutical portfolio with major exposure to immunology, oncology, neuroscience, and other healthcare markets. AERT’s gross margin improved from 24.6% to 29.1%, showing meaningful expansion in operating efficiency.
0 · Reply
GoforProMIS
GoforProMIS Aug. 19 at 4:17 PM
$PMN CEO Neil Warma attended and presented at Jefferies Healthcare, Oppenheimer CNS and at the Bio International Conference with the opportunity of 1to1 meetings. As the Alzheimer Conference took place on on 12-15 July the 4-6 week NDA analyses by the specialist of pharmaceutical companies should be done. IMO we have 5-12 pharmaceutical companies interested in PMN: Biogen /Eisai due to high Aria of Leqembi. Roche as they lost bn with Gantenerumab and need a solution. $ABBV $BMY $NVS are keen to get into neurology as partnership. Pfizer and Takeda looking for Episelect Platform!
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 19 at 3:15 PM
$SLS Yes/ Just sub in GPs and for AML --- recall $MRK Dr. Julie Cohen in Co-Authoring and Publishing the GPS Key Phase 2 Results, Recommended running a Phase 3 for GPS and Keytruda in Plat Resistant Ovarian Cancer. GPs Key Phase 2 MOS was BETTER (18.4 months) than the FDA Approved $IMGN Elahere (16.4 months) in the same exact Patient setting. $ABBV Bought IMGN for $10B based on this Data. And GPS is better.
0 · Reply
MissionControl
MissionControl Aug. 19 at 2:10 PM
$ABBV Great morning surprise. 👀
0 · Reply
HawkEye828
HawkEye828 Aug. 19 at 1:39 PM
Go Merck...PROK will easily blow past 95% once Rilparencel is appoved for Chronic Kidney disease. $PROK Analysts Sentiment Buy Price Target 6.250 Upside +369.92% prokidney.com/clinical-stud.... Phase 2 with 70% response rate for kidney disease. Phase 3 on deck. Riprencel cell therapy designed to delay or completely prevent the need for dialysis which is one of the highest Medicare expenses ...at $30 Billion a year/ 90k to 100k per patient. $RHHBY, $NVO, $LLY, $ABBV
0 · Reply
AXLFI_HQ
AXLFI_HQ Aug. 19 at 12:24 PM
$ABBV Companies are using acquisitions, divestitures, separations, and business combinations to gain scale, improve focus, unlock value, and optimize capital allocation. Learn more: https://axlfi.com/themes/379
0 · Reply
TMC101
TMC101 Aug. 19 at 10:20 AM
$ABBV 🤔
0 · Reply
KarinSparrow145
KarinSparrow145 Aug. 19 at 9:08 AM
$GENI $ABBV $SBET $DAL Genius Sports benefits from sports-data and betting partnerships, AbbVie benefits from diversified pharmaceutical demand, SBET remains highly speculative, and Delta benefits from travel demand and premium-airline activity. I'm watching contract growth, drug sales, funding, passenger demand, and margins.
0 · Reply
CDSTrading
CDSTrading Aug. 19 at 8:57 AM
$GENI $ABBV $SBET $DAL Genius Sports benefits from sports-data and betting partnerships, AbbVie benefits from diversified pharmaceutical demand, SBET remains highly speculative, and Delta benefits from travel demand and premium-airline activity. I'm watching contract growth, drug sales, funding, passenger demand, and margins.
0 · Reply
TeenageMutantNinjaTrader
TeenageMutantNinjaTrader Aug. 19 at 4:09 AM
$ABBV here we are again
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 19 at 3:49 AM
$SLS $XBI $GLSI IDMC Unblinded Actual Phase 3 MOS and Immune Response Data from the Interim Analysis on Jan 23rd ... Volume jumped from 1m'ish daily to 28M. Share Price Climbed 60% the Day Jan 28th, SLS did a RDO / $25M Cash Raise + warrants and still the Share Price / with all the Extra Shares was up 50% --- SMART MONEY - Knew Immediately Gps Was Golden ALL Pooled Survival Data Immune Response Rates --- told all the AML Industry Players. Smart Money was loading in - hand over Fist. / / When the 80th Event is ANNOUNCED -- The share Price will launch. SMART MONEY Knows what most the Inch thick mile wide retail do not. PS Since then: BAT FAILED 3 Large Phase 3 AML Trials Conducted by $ABBV including 2 for AML Remission / Transplant Maintenance.
0 · Reply
JCJustCharting
JCJustCharting Aug. 18 at 10:12 PM
$ABBV did you guy take anything with me ?https://x.com/JC_JustCharts/status/2089817358919503922?s=20
0 · Reply
WallStJesus
WallStJesus Aug. 18 at 9:25 PM
0 · Reply
l4ndsh4rk
l4ndsh4rk Aug. 18 at 7:58 PM
$ABBV Abbie V
0 · Reply
TMC101
TMC101 Aug. 18 at 3:54 PM
$ABBV Are you bullish on any stock?🤔
1 · Reply
HydrogenH2
HydrogenH2 Aug. 18 at 3:15 PM
$JNJ $ABBV I'm taking profits !! Thanks !!
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Aug. 18 at 3:04 PM
$SLS a fine point. and to underscore - $ABBV Statistical Analysis Plan (SAP) for VIALE-M - Phase 3 AML Remission Maintenance Trial - dropped the Efficacy Readout in V5.0 --- after attempting 8 Different Dosing Regimes, they quietly terminated the Trial. -- i've said this before - this trial VIALE-M / and VIALE-T were the most Serious Threats to SLS Share Holders -- if M & T were successful, it would have meant a new Higher Bar for Gps to Hurdle. --- instead, just more Toxicity and extremely poor survival.
0 · Reply
JCJustCharting
JCJustCharting Aug. 18 at 1:53 PM
$ABBV next time You should just be in my group https://x.com/jc_justcharts/status/2089712169419972938?s=46
0 · Reply
focafoca99
focafoca99 Aug. 18 at 12:15 PM
$ABBV celebrates 10th anniversary of its Immunology Scholarship, awarding 34 students with up to $20K renewable awards. https://www.rapidticker.com/news/abbv-abbvie-announces-2026-abbvie-immunology-b80051
0 · Reply
RobertBankston860
RobertBankston860 Aug. 18 at 11:40 AM
$AMTM $BOIL $VTI $ABBV Amentum benefits from government and defense-services spending, BOIL provides leveraged natural-gas exposure, VTI provides broad U.S. equity exposure, and AbbVie benefits from diversified pharmaceutical and immunology demand. I'm watching government contracts, natural-gas prices, broad-market breadth, and prescription growth.
1 · Reply
JCJustCharting
JCJustCharting Aug. 18 at 11:38 AM
$ABBV the $260 res is strong. If we can get above it, the accumulation for 8/21 on the $255+ can lead us there but vex is selling off every pop
0 · Reply